Outlook Wealth Advisors LLC Increases Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Outlook Wealth Advisors LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 35.4% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 306 shares of the company’s stock after buying an additional 80 shares during the period. Outlook Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $271,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Lynx Investment Advisory purchased a new position in shares of Eli Lilly and Company during the 2nd quarter worth about $32,000. LGT Financial Advisors LLC bought a new stake in Eli Lilly and Company in the second quarter worth about $36,000. Redmont Wealth Advisors LLC purchased a new position in shares of Eli Lilly and Company during the first quarter valued at approximately $40,000. Morton Brown Family Wealth LLC grew its stake in shares of Eli Lilly and Company by 45.5% during the second quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock valued at $41,000 after buying an additional 15 shares during the last quarter. Finally, Cedar Mountain Advisors LLC raised its holdings in shares of Eli Lilly and Company by 53.3% in the third quarter. Cedar Mountain Advisors LLC now owns 46 shares of the company’s stock worth $41,000 after buying an additional 16 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Up 0.2 %

Shares of LLY stock opened at $892.70 on Friday. The stock’s fifty day moving average price is $919.74 and its 200 day moving average price is $862.48. Eli Lilly and Company has a 1-year low of $547.61 and a 1-year high of $972.53. The company has a market cap of $848.45 billion, a price-to-earnings ratio of 109.94, a price-to-earnings-growth ratio of 3.24 and a beta of 0.42. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $1.28. The firm had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. On average, research analysts expect that Eli Lilly and Company will post 14.05 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have commented on LLY. Berenberg Bank upped their price objective on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Evercore ISI upgraded shares of Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. BMO Capital Markets lifted their price objective on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $1,025.00 target price on shares of Eli Lilly and Company in a research note on Thursday, October 3rd. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $1,106.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $1,013.41.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.